Illumina, Inc.
NMS: ILMNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Illumina, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ILMN Z-Score →About Illumina, Inc.
Healthcare
Diagnostics & Research
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Illumina, Inc. demonstrates exceptional profitability, with a profit margin of 19.6%.
The company recently reported 5.0% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 33.4%, which reflects exceptional capital efficiency.
At a current price of $120.93, ILMN currently sits at the 60th percentile of its 52-week range (Range: $69.83 - $155.53).
💰 Valuation Insight
ILMN is valued broadly in line with the sector at a PE of 22.19. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$18.49B
Trailing P/E
22.19
Forward P/E
20.75
Beta (5Y)
1.49
52W High
$155.53
52W Low
$69.83
Avg Volume
1.99M
Day High
Day Low